Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nimotuzumab + finotonlimab + chemotherapy for resectable locally advanced oral squamous cell carcinoma
ChiCTR2600126361Phase 2Recruiting
- Sponsor
- School of Stomatology, Fourth Military Medical University
- Start
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab, finotonlimab, paclitaxel and cisplatin in Oral Mucosal Carcinoma, sponsored by School of Stomatology, Fourth Military Medical University. Primary endpoint: Major Pathologic Response (MPR) rate. Started Jun 2026; status: recruiting.
02
Drugs
nimotuzumabfinotonlimabpaclitaxelcisplatin
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600126361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126361.